Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment
Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex virus type 1 oncolytic virus and a component of MB-109, designed to treat malignant glioma.
Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex virus type 1 oncolytic virus and a component of MB-109, designed to treat malignant glioma.
What's Your Reaction?
